KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) EPS (Basic) (2016 - 2025)

Vertex Pharmaceuticals has reported EPS (Basic) over the past 17 years, most recently at $4.69 for Q4 2025.

  • Quarterly results put EPS (Basic) at $4.69 for Q4 2025, up 32.86% from a year ago — trailing twelve months through Dec 2025 was $15.47 (up 843.75% YoY), and the annual figure for FY2025 was $15.46, up 843.27%.
  • EPS (Basic) for Q4 2025 was $4.69 at Vertex Pharmaceuticals, up from $4.24 in the prior quarter.
  • Over the last five years, EPS (Basic) for VRTX hit a ceiling of $4.69 in Q4 2025 and a floor of -$13.92 in Q2 2024.
  • Median EPS (Basic) over the past 5 years was $3.42 (2021), compared with a mean of $2.48.
  • Biggest five-year swings in EPS (Basic): skyrocketed 1119.23% in 2022 and later plummeted 492.11% in 2024.
  • Vertex Pharmaceuticals' EPS (Basic) stood at $3.01 in 2021, then rose by 5.98% to $3.19 in 2022, then grew by 17.87% to $3.76 in 2023, then decreased by 6.12% to $3.53 in 2024, then soared by 32.86% to $4.69 in 2025.
  • The last three reported values for EPS (Basic) were $4.69 (Q4 2025), $4.24 (Q3 2025), and $4.02 (Q2 2025) per Business Quant data.